Texas-based company Castle Biosciences has published results of a study investigating its DecisionDx cutaneous squamous cell carcinoma (SCC) test designed to guide patient selection for adjuvant radiation therapy (ART), which could save the US Medicare service $972 million annually.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,